Intranasal ketamine delivers a rapid antidepressant effect in patients with treatment-resistant major depressive disorder (MDD), new research shows. Investigators report that the N-methyl-D-asparate ...

The Food and Drug Administration has approved a variant of the anesthetic and party drug ketamine for suicidal patients with major depression. The drug is a nasal spray called Spravato and it contains ...

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the publication of results from its ongoing Phase 2a clinical study ...

A new large-scale clinical trial suggests that esketamine nasal spray, used on its own, may offer meaningful relief for adults with treatment-resistant depression. Participants who received esketamine ...

Add Yahoo as a preferred source to see more of our stories on Google. Ozark Center has opened a new site providing treatments for patients with depression who are resistant to traditional therapies.

A new nasal spray, with compounds similar to ketamine, is being recommended by the FDA as a depression treatment. The nasal spray will be used for patients who haven't had success using ...

Patients are commonly diagnosed with treatment-resistant depression when they do not improve despite receiving two or more pharmacologic treatments for an adequate dose and duration during the same ...